These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26214579)

  • 1. Inhibition of Light Chain 6aJL2-R24G Amyloid Fiber Formation Associated with Light Chain Amyloidosis.
    Pelaez-Aguilar AE; Rivillas-Acevedo L; French-Pacheco L; Valdes-Garcia G; Maya-Martinez R; Pastor N; Amero C
    Biochemistry; 2015 Aug; 54(32):4978-86. PubMed ID: 26214579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cu(II) binding to the λ6aJL2-R24G antibody light chain protein associated with light chain amyloidosis disease: The role of histidines.
    Pelaez-Aguilar AE; Mata-Salgado F; Morales-Ortiz A; Millán-Pacheco C; Olvera-Carranza C; Salgado-Delgado J; Pastor N; Rivillas-Acevedo L
    Int J Biol Macromol; 2024 Jun; 270(Pt 2):132393. PubMed ID: 38761898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solution structure of 6aJL2 and 6aJL2-R24G amyloidogenics light chain proteins.
    Maya-Martinez R; Gil-Rodriguez P; Amero C
    Biochem Biophys Res Commun; 2015 Jan; 456(2):695-9. PubMed ID: 25522882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Dynamics in 6aJL2 Proteins Associated with AL Amyloidosis, a Conformational Disease.
    Maya-Martinez R; French-Pacheco L; Valdés-García G; Pastor N; Amero C
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31438515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (1)H, (15)N and (13)C resonance assignments for 3rC and 3rCWP: amyloidogenic variants of imunoglobulin λ 3 light-chain.
    Gil-Rodríguez P; Amero C
    Biomol NMR Assign; 2015 Apr; 9(1):139-42. PubMed ID: 24816896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain.
    Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D
    Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-Specific Interactions with Copper Promote Amyloid Fibril Formation for λ6aJL2-R24G.
    Pelaez-Aguilar AE; Valdés-García G; French-Pacheco L; Pastor N; Amero C; Rivillas-Acevedo L
    ACS Omega; 2020 Apr; 5(13):7085-7095. PubMed ID: 32280849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational and genetic determinants of λ6 light chain amyloidogenesis.
    González-Andrade M; Becerril-Luján B; Sánchez-López R; Ceceña-Álvarez H; Pérez-Carreón JI; Ortiz E; Fernández-Velasco DA; del Pozo-Yauner L
    FEBS J; 2013 Dec; 280(23):6173-83. PubMed ID: 24107228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of amyloid fibril formation in the variable domain of λ6 light chain mutant Wil caused by the interaction between its unfolded state and epigallocatechin-3-O-gallate.
    Abe Y; Odawara N; Aeimhirunkailas N; Shibata H; Fujisaki N; Tachibana H; Ueda T
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2570-2578. PubMed ID: 30251653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of 6aJL2-R24G light chain variable domain: Does crystal packing explain amyloid fibril formation?
    Rudiño-Piñera E; Peláez-Aguilar ÁE; Amero C; Díaz-Vilchis A
    Biochem Biophys Rep; 2019 Dec; 20():100682. PubMed ID: 31517067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
    Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
    J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis.
    Hernández-Santoyo A; del Pozo Yauner L; Fuentes-Silva D; Ortiz E; Rudiño-Piñera E; Sánchez-López R; Horjales E; Becerril B; Rodríguez-Romero A
    J Mol Biol; 2010 Feb; 396(2):280-92. PubMed ID: 19941869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI.
    Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D
    FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
    Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
    J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli.
    Rognoni P; Lavatelli F; Casarini S; Palladini G; Verga L; Pedrazzoli P; Valentini G; Merlini G; Perfetti V
    PLoS One; 2013; 8(9):e76022. PubMed ID: 24086679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains.
    del Pozo Yauner L; Ortiz E; Sánchez R; Sánchez-López R; Güereca L; Murphy CL; Allen A; Wall JS; Fernández-Velasco DA; Solomon A; Becerril B
    Proteins; 2008 Aug; 72(2):684-92. PubMed ID: 18260098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
    Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
    Elife; 2020 Mar; 9():. PubMed ID: 32151314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compound screening identified gossypetin and isoquercitrin as novel inhibitors for amyloid fibril formations of Vλ6 proteins associated with AL amyloidosis.
    Takahashi D; Matsunaga E; Yamashita T; Caaveiro JMM; Abe Y; Ueda T
    Biochem Biophys Res Commun; 2022 Mar; 596():22-28. PubMed ID: 35108650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
    Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
    PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of amyloid fiber assembly by both BiP and its target peptide.
    Davis PD; Raffen R; Dul LJ; Vogen MS; Williamson KE; Stevens JF; Argon Y
    Immunity; 2000 Oct; 13(4):433-42. PubMed ID: 11070162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.